Literature DB >> 16113673

Survival after reduced-intensity conditioning is not inferior to standard high-dose conditioning before allogeneic haematopoietic cell transplantation in acute leukaemias.

G Massenkeil1, M Nagy, S Neuburger, I Tamm, C Lutz, P le Coutre, O Rosen, K-D Wernecke, B Dörken, R Arnold.   

Abstract

To assess the role of allogeneic stem cell transplantation (SCT) after reduced-intensity conditioning (RIC) in acute leukaemias, we retrospectively compared 25 patients with acute lymphoblastic leukaemia or acute myelogenous leukaemia after RIC to a historical group of 50 matched controls after high-dose conditioning. Engraftment, acute GvHD and severe infections were comparable in both groups. During the observation period, 1/25 patients (4%) after RIC and 14/50 (28%) after standard SCT died due to transplant-related causes; cumulative nonrelapse mortality (NRM) was 4% after RIC and 24% after standard SCT (P=0.029). In total, 15/25 patients (60%) relapsed after RIC and 20/50 (40%) after standard SCT; probability of disease-free survival (DFS) at 3 years was 43% after RIC and 49% after standard SCT (NS). Overall survival (OS) was 40% after RIC and 37% after standard SCT (NS). Stage of disease, cytogenetic risk profile, acute and chronic GvHD, chimerism status at day 90 and severe infections after transplantation were risk factors with significant impact on DFS and/or OS. In retrospective analysis, patients with acute leukaemias who receive RIC because of contraindications against standard SCT have a comparable outcome to standard SCT, but the higher relapse rate warrants further studies.

Entities:  

Mesh:

Year:  2005        PMID: 16113673     DOI: 10.1038/sj.bmt.1705123

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  13 in total

1.  Comparison of reduced-intensity conditioning regimens in patients with acute lymphoblastic leukemia >45 years undergoing allogeneic stem cell transplantation-a retrospective study by the Acute Leukemia Working Party of EBMT.

Authors:  Zinaida Peric; Myriam Labopin; Christophe Peczynski; Emmanuelle Polge; Jan Cornelissen; Ben Carpenter; Mike Potter; Ram Malladi; Jenny Byrne; Harry Schouten; Nathalie Fegueux; Gerard Socié; Montserrat Rovira; Jurgen Kuball; Maria Gilleece; Sebastian Giebel; Arnon Nagler; Mohamad Mohty
Journal:  Bone Marrow Transplant       Date:  2020-05-02       Impact factor: 5.483

Review 2.  Indications and outcomes of reduced-toxicity hematopoietic stem cell transplantation in adult patients with hematological malignancies.

Authors:  S Fadilah Abdul Wahid
Journal:  Int J Hematol       Date:  2013-04-13       Impact factor: 2.490

Review 3.  Who Should Receive a Transplant for Acute Lymphoblastic Leukaemia?

Authors:  Rishi Dhawan; David I Marks
Journal:  Curr Hematol Malig Rep       Date:  2017-04       Impact factor: 3.952

Review 4.  NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation.

Authors:  Steven Z Pavletic; Shaji Kumar; Mohamad Mohty; Marcos de Lima; James M Foran; Marcelo Pasquini; Mei-Jie Zhang; Sergio Giralt; Michael R Bishop; Daniel Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2010-04-24       Impact factor: 5.742

5.  Reduced intensity conditioning prior to allogeneic stem cell transplantation in first complete remission is effective in patients with acute myeloid leukemia and an intermediate-risk karyotype.

Authors:  Philipp G Hemmati; Theis H Terwey; Gero Massenkeil; Philipp le Coutre; Lam G Vuong; Stefan Neuburger; Bernd Dörken; Renate Arnold
Journal:  Int J Hematol       Date:  2010-02-25       Impact factor: 2.490

6.  The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission.

Authors:  David I Marks; Tao Wang; Waleska S Pérez; Joseph H Antin; Edward Copelan; Robert Peter Gale; Biju George; Vikas Gupta; Joerg Halter; H Jean Khoury; Thomas R Klumpp; Hillard M Lazarus; Victor A Lewis; Philip McCarthy; David A Rizzieri; Mitchell Sabloff; Jeff Szer; Martin S Tallman; Daniel J Weisdorf
Journal:  Blood       Date:  2010-04-19       Impact factor: 22.113

7.  Myeloablative irradiation in non-human primates.

Authors:  K L Watts; B C Beard; B L Wood; H P Kiem
Journal:  J Med Primatol       Date:  2009-07-22       Impact factor: 0.667

8.  Ineffective vaccination against solid tumors can be enhanced by hematopoietic cell transplantation.

Authors:  Alexander Filatenkov; Antonia M S Müller; William Wei-Lin Tseng; Sussan Dejbakhsh-Jones; Daniel Winer; Richard Luong; Judith A Shizuru; Edgar G Engleman; Samuel Strober
Journal:  J Immunol       Date:  2009-11-04       Impact factor: 5.422

9.  Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission.

Authors:  David I Marks; Waleska S Pérez; Wensheng He; Mei-Jie Zhang; Michael R Bishop; Brian J Bolwell; Christopher N Bredeson; Edward A Copelan; Robert Peter Gale; Vikas Gupta; Gregory A Hale; Luis M Isola; Ann A Jakubowski; Armand Keating; Thomas R Klumpp; Hillard M Lazarus; Jane L Liesveld; Richard T Maziarz; Philip L McCarthy; Mitchell Sabloff; Gary Schiller; Jorge Sierra; Martin S Tallman; Edmund K Waller; Peter H Wiernik; Daniel J Weisdorf
Journal:  Blood       Date:  2008-04-08       Impact factor: 22.113

Review 10.  Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis.

Authors:  S Fadilah Abdul Wahid; Nor-Azimah Ismail; Mohd-Razif Mohd-Idris; Fariza Wan Jamaluddin; NorRafeah Tumian; Ernie Yap Sze-Wei; Norasiah Muhammad; Ming Lai Nai
Journal:  Stem Cells Dev       Date:  2014-09-17       Impact factor: 3.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.